Genovis
28.5 SEK +9.83%1,674 investors are following this company
Genovis is active in biotechnology. The greatest focus in the business is on the development of enzymes used in various pharmaceuticals. The company's patented NIMT technology is developed to make it easier for the LifeScience industry to conduct preclinical research. The company's products are resold under a number of brands. Genovis was established in 1999 and is headquartered in Lund.
Revenue
158.23M
EBIT %
34.27 %
P/E
30.32
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
GENO
Daily low / high price
25.65 / 28.5
SEK
Market cap
1.87B SEK
Turnover
4.44M SEK
Volume
168K
Financial calendar
General meeting
2024-05-15
Interim report
2024-05-15
Interim report
2024-08-20
Interim report
2024-11-08
Annual report
2025-02-14
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Mikael Lönn | 14.5 % | 14.5 % |
State Street Bank And Trust Co, W9 | 8.4 % | 8.4 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Genovis AB: Genovis årsredovisning 2023 publicerad
Genovis AB: KALLELSE TILL ÅRSSTÄMMA 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools